Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
26.77
-0.77 (-2.80%)
At close: Oct 10, 2025, 4:00 PM EDT
26.77
0.00 (0.00%)
After-hours: Oct 10, 2025, 4:00 PM EDT
Celldex Therapeutics Revenue
Celldex Therapeutics had revenue of $730.00K in the quarter ending June 30, 2025, a decrease of -70.78%. This brings the company's revenue in the last twelve months to $5.79M, down -30.25% year-over-year. In the year 2024, Celldex Therapeutics had annual revenue of $7.02M with 1.99% growth.
Revenue (ttm)
$5.79M
Revenue Growth
-30.25%
P/S Ratio
308.86
Revenue / Employee
$31,129
Employees
186
Market Cap
1.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.02M | 137.00K | 1.99% |
Dec 31, 2023 | 6.88M | 4.53M | 192.02% |
Dec 31, 2022 | 2.36M | -2.29M | -49.32% |
Dec 31, 2021 | 4.65M | -2.77M | -37.30% |
Dec 31, 2020 | 7.42M | 3.85M | 107.61% |
Dec 31, 2019 | 3.57M | -5.97M | -62.54% |
Dec 31, 2018 | 9.54M | -3.21M | -25.15% |
Dec 31, 2017 | 12.74M | 5.96M | 87.78% |
Dec 31, 2016 | 6.79M | 1.31M | 23.83% |
Dec 31, 2015 | 5.48M | 1.89M | 52.82% |
Dec 31, 2014 | 3.59M | -525.00K | -12.77% |
Dec 31, 2013 | 4.11M | -7.09M | -63.30% |
Dec 31, 2012 | 11.20M | 1.94M | 20.91% |
Dec 31, 2011 | 9.27M | -37.53M | -80.20% |
Dec 31, 2010 | 46.79M | 31.61M | 208.25% |
Dec 31, 2009 | 15.18M | 7.72M | 103.59% |
Dec 31, 2008 | 7.46M | 6.05M | 430.30% |
Dec 31, 2007 | 1.41M | 506.82K | 56.36% |
Dec 31, 2006 | 899.18K | -2.19M | -70.88% |
Dec 31, 2005 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CLDX News
- 23 days ago - Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 - GlobeNewsWire
- 4 weeks ago - Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Celldex: Despite Dropping Eosinophilic Esophagitis Program, Barzolvolimab On Track - Seeking Alpha
- 7 weeks ago - Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short - Benzinga
- 7 weeks ago - Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewsWire
- 2 months ago - Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 - GlobeNewsWire